Beware of boilerplate: Practical lessons for patent drafting from G1/24 (Claim interpretation)
Following the high profile hearing last month, we are now all waiting with bated breath for the written decision of the Enlarged Board of...
Following the high profile hearing last month, we are now all waiting with bated breath for the written decision of the Enlarged Board of...
The EPO Board of Appeal decision in T 0687/22 confirms beyond doubt the relevance of G 2/21 to software inventions. The decision in ...
The recent decision T 1913/21 highlights a crucial differentiation between second non-medical use claims and process claims. The Board...
The decision in T 0660/22 combines two hot topics, AI and cells! The patent application at issue related to a method for analysing...
The recent Board of Appeal decision in T 1977/22 related to the patentability of claims defining subject matter with open-ended...
The Board of Appeal decision in T 2130/22 considered the inventive step of a pharmaceutical formulation in which the technical effect...
Cell therapy is a highly innovative therapeutic strategy that uses living cells to combat disease. Cell therapy strategies include stem...
The Board of Appeal decision in T 2543/22 relates to a manufacturing method for preparing a therapeutic peptide. The Board of Appeal...
The Board of Appeal decision in T 0295/22 tackles the question of whether a new mode of administration of a drug should be considered a...
The Enlarged Board of Appeal (EBA) has issued its preliminary opinion in the closely watched referral G1/24 relating to the role of the...